
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific's positive outlook is supported by anticipated growth in critical medical procedure markets, with a projected 5-10% increase in combined atrial fibrillation (AF) ablation and left atrial appendage closure (LAAC) procedures stemming from recent trial results. The company's forecasts indicate that the global AFib market may expand from $9 billion to $15 billion by 2028, showcasing a compound annual growth rate (CAGR) that is expected to drive significant revenue increases, particularly as newer technologies and catheters are introduced. Additionally, positive survey results from healthcare professionals suggest an expectation of a substantial volume increase in procedures, averaging around 18%, following the outcomes of pivotal trials, highlighting strong market confidence and demand for Boston Scientific's innovative products.
Bears say
Boston Scientific is facing a negative outlook primarily due to a significant decline in the market shares of its radiofrequency (RF) and cryoablation products, with RF procedures projected to decrease from 34% to 23% and cryoablation from 25% to 20% by 2030. Additionally, the company is grappling with challenges such as slower-than-expected uptake of its product portfolio, limited operating leverage, and heightened debt levels, all of which could adversely impact financial performance and growth. Furthermore, ongoing pricing pressures in its core businesses, combined with risks from new competitors and potential delays in product approvals, pose further threats to Boston Scientific’s future profitability.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares